Drug and Drug-like Molecule Binding to Interface of SARS-CoV-2 Sprotein:human ACE2 Complex: A Density Functional Theory Study
SARS-CoV-2 S-protein:human ACE2 complex models.<div>QM-MM optimized active site model of SARS-CoV-2 S-protein:human ACE2 interface.</div><div>ONIOM(B3LYP/6-31G*:PM7) method is the chosen QM-MM method. </div><div> DFT B3LYP/6-31G* level data on energetics is reported for drug-receptor interaction.</div><div>Several FDA approved drugs and traditional herbal isolates are modelled.</div><div>Used Gaussian16 to model the systems.</div><div><br></div><div><br></div><p>The interface cavity of SARS-CoV-2 S-protein:human ACE2 complex (<b>M</b>) for ligand (<b>L</b>) binding is modelled using a two layer ONIOM(B3LYP/6-31G*:PM7) method for sixteen traditional herbal isolates (THI) and nineteen drugs. The binding energy (E<sub>b</sub>) of <b>ML</b> complexes increased with increase in dipole moment of <b>L</b>s. E<sub>b</sub> better than -80.0 kcal/mol is observed for digallic acid and adenosine 3',5'-bisphosphate whereas myricetin, glucogallin, sapropterin, tetrahydrobiopterin, protirelin and fidarestat<b> </b>showed E<sub>b</sub> better than -60.0 kcal/mol. Multiple noncovalent interactions emanating from arginine, histidine, tyrosine, lysine, carboxylate and amide units (total around 6 - 8) of <b>L</b>, S-protein and ACE2 receptors provide the high binding energy. The sugar substitute aspartame modified with myricetin unit showed the best E<sub>b</sub> -91.7 kcal/mol. ONIOM-linked DFT study is effective, affordable and reliable for a quantum chemical rational design approach to model drug-receptor binding process for COVID-19 drug development which sheds light upon the noncovalent binding features of receptor cavity.</p>